Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Analyst Ratings

• Total Analysts: 2
• Consensus Rating: Strong Buy
• Price Target: $6.25
• Upside: +274.25%

Ratings History

Filter results

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $6.5 → $5.5	Strong Buy	Maintains	$6.5 → $5.5	+229.34%	Dec 3, 2025
Yi Chen HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $7	Strong Buy	Initiates	$7	+319.16%	Nov 17, 2025
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $6.2 → $6.5	Strong Buy	Maintains	$6.2 → $6.5	+289.22%	Sep 9, 2025
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $6.6 → $6.2	Strong Buy	Maintains	$6.6 → $6.2	+271.26%	Apr 15, 2025
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Reiterates $6.6	Strong Buy	Reiterates	$6.6	+295.21%	Nov 20, 2024
Scott Henry Alliance Global Partners	Alliance Global Partners	Strong Buy Maintains $8.25 → $6	Strong Buy	Maintains	$8.25 → $6	+259.28%	Nov 19, 2024
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $6.4 → $6.6	Strong Buy	Maintains	$6.4 → $6.6	+295.21%	Aug 20, 2024
Edward Woo Ascendiant Capital	Ascendiant Capital	Strong Buy Initiates $63	Strong Buy	Initiates	$63	+3,642.51%	Jan 17, 2023
Scott Henry Roth Capital	Roth Capital	Strong Buy Maintains $275 → $250	Strong Buy	Maintains	$275 → $250	+14,870.06%	Aug 13, 2021
Scott Henry Roth Capital	Roth Capital	Strong Buy Maintains $300 → $275	Strong Buy	Maintains	$300 → $275	+16,367.07%	May 18, 2021
Alexander Nowak Craig-Hallum	Craig-Hallum	Strong Buy Initiates $300	Strong Buy	Initiates	$300	+17,864.07%	Jan 11, 2021
Scott Henry Roth Capital	Roth Capital	Strong Buy Initiates $300	Strong Buy	Initiates	$300	+17,864.07%	Jan 5, 2021